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Background: Liver disease (LD) prolongs mirtazapine half-life in humans, but it is unknown if this
occurs in cats with LD and healthy cats.
Hypothesis/Objectives: To determine pharmacokinetics of administered orally mirtazapine
in vivo and in vitro (liver microsomes) in cats with LD and healthy cats.
Animals: Eleven LD and 11 age-matched control cats.
Methods: Case-control study. Serum was obtained 1 and 4 hours (22 cats) and 24 hours (14 cats)
after oral administration of 1.88 mg mirtazapine. Mirtazapine concentrations were measured by liq-
uid chromatography with tandem mass spectrometry. Drug exposure and half-life were predicted
using limited sampling modeling and estimated using noncompartmental methods. in vitro mirtaza-
pine pharmacokinetics were assessed using liver microsomes from 3 LD cats and 4 cats
without LD.
Results: There was a significant difference in time to maximum serum concentration between
LD cats and control cats (median [range]: 4 [1-4] hours versus 1 [1-4] hours; P = .03). The cal-
culated half-life of LD cats was significantly prolonged compared to controls (median [range]:
13.8 [7.9-61.4] hours versus 7.4 [6.7-9.1] hours; P < .002). Mirtazapine half-life was corre-
lated with ALT (P = .002; r = .76), ALP (P < .0001; r = .89), and total bilirubin (P = .0008;
r = .81). The rate of loss of mirtazapine was significantly different between microsomes of
LD cats (–0.0022 min−1, CI: −0.0050 to 0.00054 min−1) and cats without LD (0.01849 min−1,
CI: −0.025 to −0.012 min−1; P = .002).
Conclusions and Clinical Importance: Cats with LD might require less frequent administration
of mirtazapine than normal cats.
KEYWORDS
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1 | INTRODUCTION
Mirtazapine is an appetite stimulant that has become a common treat-
ment for supportive care in sick cats.1 In humans, several factors can
affect the metabolism of mirtazapine, including age, renal and hepatic
impairment.2 In cats, renal disease decreases clearance, but the effect
of liver disease (LD) is unknown.3 Mirtazapine is primarily metabolized
by the liver, initially by demethylation and oxidation, and then by con-
jugation to glucuronic acid.2 Hepatic impairment can cause as much as
a 33% decrease in clearance and a 39% increase in the half-life of
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMC,
age-matched control; AUC, area under the curve; CL, clearance; F, bioavailabil-
ity; HB, homogenization buffer; Kel, estimation of elimination rate; LC/MS/MS,
liquid chromatography/tandem mass spectrometry; LLOQ, lower limit of quanti-
tation; QA/QC, quality assurance, quality control; NADPH, nicotinamide ade-
nine dinucleotide phosphate; T1/2, half-life; Vd, volume of distribution.
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mirtazapine in humans, thus in patients with LD the drug is adminis-
tered less frequently.2 The purpose of this study was to compare the
pharmacokinetics of mirtazapine administered PO in cats with LD
compared with age matched healthy control cats using a limited sam-
pling strategy based on the pharmacokinetic modeling in healthy
cats.4 The secondary purpose was to use liver microsomes obtained
from cats with and without LD to compare the pharmacokinetics of
mirtazapine in vitro. Our hypothesis was that cats with LD would have
prolonged half-life of mirtazapine compared to cats without LD.
2 | MATERIALS AND METHODS
2.1 | In vivo studies
2.1.1 | Cats
Cats were categorized into one of the following groups: healthy age-
matched controls and cats with LD. Healthy age-matched control
cats were defined as having a normal CBC, serum biochemistry
(creatinine ≤ 1.6 mg/dL), urinalysis (USG > 1.035) and total T4 level.
Exclusion criteria for age-matched control cats included other sys-
temic illness, diabetes, inflammatory bowel disease, hyperthyroidism,
cancer, LD, or heart disease. Cats with LD were defined based on
increased activity of liver-derived alanine aminotransferase (ALT)
enzyme (> 200 UI/L) or total bilirubin (>1 mg/dL) without clinical sus-
picion of prehepatic or posthepatic hyperbilirubinemia. Exclusion cri-
teria for LD cats included hyperthyroidism or chronic kidney disease
(defined as creatinine > 1.6 mg/dL and USG < 1.035). Age matching
was performed by enrolling healthy control cats that were within
1 year of the age of an enrolled LD cat. The study was approved by
the Institutional Animal Care and Use Committee at Colorado State
University and all owners reviewed and signed consent forms before
enrolling their cat in the study.
2.1.2 | Drug preparation
Commercially available generic 15 mg mirtazapine tablets
(Amerisourcebergen, Chesterbrook, Pennsylvania) were compounded
into 1.88 mg capsule doses by the pharmacy at the Colorado State
University Veterinary Teaching Hospital according to the Professional
Compounding Centers of America protocol as previously described.4
Mirtazapine capsules were compounded within 1 month of use and
stored at room temperature.
2.1.3 | Dosing and sampling
Eleven cats with LD and 11 age-matched control cats received
1.88 mg mirtazapine once PO. Serum was obtained at 1, 4, and, when
possible, 24 hours after drug administration. Sampling time points
were determined with limited sampling modeling (described below)
based on pharmacokinetic assessment of mirtazapine in young and
old normal cats.3,4 Serum was collected via centrifugation immediately
after clot formation and frozen in aliquots at −80C until analysis.
2.1.4 | Mirtazapine sample extraction and evaluation
Mirtazapine was measured using liquid chromatography/tandem mass
spectrometry (LC/MS/MS) by the Pharmacology Core at Colorado
State University using a validated LC/MS/MS based assay for the
analysis of mirtazapine in feline serum.4 Assay performance for each
batch was assessed using at least 10% quality assurance, quality con-
trol (QA/QC) samples dispersed among unknown samples at low
(1 ng/mL), mid (10 ng/mL), and high (100 ng/mL) ranges of the stan-
dard curve (0.5–500 ng/mL) with batches failing if >25% of the
QA/QC samples were outside of the accepted level of 85% accuracy.
Accuracy of QA/QC samples among the batches analyzed for this
study ranged from 94.5 ± 4.6 to 92.2 ± 6.8%. The lower limit of quan-
titation (LLOQ) for this assay was based on the level of detection with
>85% accuracy and a coefficient of variation (%) <15%, and was deter-
mined to be 0.5 ng/mL. Assay performance was linear to >500 ng/mL,
but 500 ng/mL was used as the upper limit of the assay as utilized
because of a lack of samples exceeding this concentration.
2.1.5 | Limited sampling modeling and pharmacokinetic
analysis
The mirtazapine serum concentration versus time data for 10 healthy
cats administered a fixed oral 1.88 mg dose in two earlier studies was
used for calculation of drug exposure (AUC0–24 h) by noncompartmen-
tal methods.3,4 The resulting AUC values were found to be normally
distributed by Q–Q plot and subsequently analyzed as a response to
time point mirtazapine concentration values as predictors by best sub-
set multiple linear regression. This method evaluates all single time
points as well as all possible combinations of multiple time points as
predictors of the outcome (AUC0–24 h). Data used in the best subset
linear regression analysis were those time points corresponding to
postadministration samples and were designated as 0.5, 1, 1.5, 2, 4,
8, 12, and 24 corresponding to the number of hours the samples were
collected after administration. The combinations of statistical correla-
tion, number of samples required, and length of time required after
administration were all considered in choosing the optimal limited
sampling scheme. All regression analysis was carried out using Minitab
v 15.1.1.0 software (Minitab, State College, Pennsylvania). The results
of best subset multiple linear regression revealed that using 2 points
as predictors of AUC0-infinity (1 and 4 hours) could provide the best
combination of statistical correlation (r2 = 0.989) while minimizing
sample number and time postadministration. The final model using
the identified time points is described by the equation
AUC0− infinity = −129 + ð3:25∗C1 hourÞ + ð12:0∗C4 hoursÞ
where C1 hour and C4 hours represent the serum concentrations at
1 and 4 hours, respectively, after oral administration. This equation
was used to estimate AUC in study samples.
A 24 hours time point was included when possible for the estima-
tion of elimination rate (Kel), which was calculated with the 4 and
24 hours time points using the equation:
Kel = lnðC24 hours=C4 hoursÞ=ð24−4Þ
Half-life was then calculated using the equation:
T1=2 = 0:693=Kel
The 24 hours time point was chosen to provide a more accurate
estimation of elimination while still maintaining serum concentrations
that are above the LLOQ of the analytical assay. Cmax was reported as
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the highest measured serum concentration (either 1 or 4 hours) and
Tmax was reported as the time point corresponding to the highest
measured serum concentration.
2.1.6 | Statistical analysis
Pharmacokinetic parameters were compared between the 2 groups using
repeated Mann Whitney test in Prism software (Prism 5; GraphPad, La
Jolla, California). Parameters compared included AUC, Cmax (maximum
serum concentration), and Tmax (time to maximum serum concentration),
and in the cats where a 24 hours sample was obtained, half-life. Mann
Whitney test was also used to compare, age, mg/kg dose, serum ALT
activity, alkaline phosphatase activity (ALP), total bilirubin, and albumin
concentrations between groups. Spearman rank test was used to assess
correlation between ALT, ALP, total bilirubin, albumin, and half-life. For
all analyses, a P-value < .05 was considered statistically significant.
2.2 | In vitro studies
2.2.1 | Collection of liver microsomes
Liver samples for microsome isolation were collected at necropsy
within 30 minutes of euthanasia from 3 LD cats (hepatic lipidosis) and
4 cats with normal CBC, serum biochemistry and urinalysis. Euthana-
sia was not performed for the purpose of the study. Age matching
was not possible in the in vitro study. One LD cat from which micro-
somes were collected had also been enrolled in the in vivo study, but
had not received mirtazapine for more than a week before humane
euthanasia (a feeding tube was in place). Samples were flash frozen in
liquid nitrogen and stored at −80C until microsome isolation.
2.2.2 | Liver microsome preparation
Microsomes from liver pieces were prepared by a differential centrifuga-
tion method. All steps were carried out at 4C or on ice. Liver pieces
were homogenized in buffer (HB: 100 mM sucrose, 1 mM EDTA) in a
dounce homogenizer at a 100 mg-liver-weight/mL-HB ratio. Homoge-
nates were subjected to the following differential centrifugation scheme:
800g for 10 minutes, 7000g for 10 minutes, 18 000g for 5 minutes, and
100 000g for 60 minutes. After each spin, the supernatant was trans-
ferred to a new tube and the pellet was discarded except after the final
spin. The pellet after the final spin, which contains microsomes, was kept
and resuspended gently in a small volume (100–400 μL) of HB and
stored at −80C. A small aliquot was taken for protein concentration
determination by bicinchoninic acid assay. The protein content of the
samples was adjusted after measurement to 1.5 mg/mL microsomal pro-
tein. Microsome aliquots were thawed on ice when needed and aliquots
were not used more than three freeze/thaw cycles.
2.2.3 | Liver microsome incubations
Liver microsomes were incubated with mirtazapine for a total time of
80 minutes, and loss of mirtazapine was determined. Incubations were
performed in 0.1 M phosphate buffer (44 mM KH2PO4, 56 mM
K2HPO4), adjusted to pH 7.43 with 1.0 M NaOH. Reaction master
mixes were prepared with a nicotinamide adenine dinucleotide phos-
phate (NADPH) regenerating system (Gentest NADPH Regenerating
System, Corning, NY) which facilitates stability of microsomes for up
to 2 hours. The amount of regenerating system ensured a roughly
constant concentration of NAPDH at 1.5 mM. Reaction master mixes
were preincubated at 37C for 5 minutes. Metabolism reactions were
initiated by the addition of 100 ng/mL mirtazapine and incubated at
37C. Time points were taken at 0, 20, 40, 60, and 80 minutes. At
each time point, 100 μL of reaction mix was removed and mixed 1 : 1
with acetonitrile. Samples were vortexed and stored at −80C until
ready for analysis.
After incubation, samples were processed for analysis by LC/MS/
MS using the previously validated method for mirtazapine analysis in
feline serum.4 Samples were thawed, internal standard (trazodone
25 ng/mL) was spiked into each reaction, and then samples were spun
at 18 000g for 5 minutes at 4C. The supernatant was removed and
put into mass spectrometry vials for analysis. Mirtazapine was quantified
via multiple reaction monitoring, and by integration of the chromato-
graphic peaks associated with the analyte. Concentrations were based
on the ratio of mirtazapine : internal standard using Analyst (AB Sciex)
software. Standards and QCs were prepared in microsomes similar to
incubation reactions to account for any matrix effects in the samples.
2.2.4 | Statistical analysis
To calculate the in vitro half-life of mirtazapine, the fraction mirtaza-
pine remaining in the incubation samples was converted to percent-
age remaining and natural log transformed before least squares
(ordinary) fit nonlinear regression (straight line). A repeated measures
two-way ANOVA was used to compare the in vitro kel (slope of the
line in least squares nonlinear regression) of mirtazapine between LD
cats and non-LD cats. Calculation of the in vitro half-life was per-
formed by dividing 0.693 by the in vitro kel : t1/2 = 0.693/kel.
The apparent intrinsic hepatic clearance (CLint,app) of mirtazapine
was then calculated using the in vitro half-life as follows:
CLint,app = ð0:693=in vitrot1=2Þ
ðincubation volume=mg of microsomal proteinÞ
ðmg microsomal protein=gram of liverÞ
ðgrams of liver=kg body weightÞ11
Values for mg of microsomal protein per gram of liver (21.3 mg)
and grams of liver per kg of body weight (24.6 g) for cats were taken
from previously published literature.5,6
3 | RESULTS
3.1 | In vivo studies
The average age of LD cats was 8.8 +/– 4.2 years (range 2–15 years).
There were 5 spayed female cats and 6 castrated male cats. The average
age of age-matched control cats was 8.3 +/– 3.9 years (range 2–13
years). There were 8 spayed female cats and 3 castrated male cats.
There was no significant difference in age between groups (P = .66).
Values for serum ALT activity, serum ALP activity, serum total bilirubin
concentration, serum albumin concentration, and dose of mirtazapine
(mg/kg) for both groups are presented in Table 1. There was a statisti-
cally significant elevation in serum ALT activity (P < .0001), serum ALP
activity (P < .0002), and serum total bilirubin concentration (P < .0001)
in LD cats when compared to age-matched control cats. All cats
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tolerated oral administration of mirtazapine. There was no statistically
significant difference noted in the dose of mirtazapine administered
between LD cats and age-matched control cats (0.43 +/– 0.1 versus
0.47 +/– 0.1 mg/kg; P = .53). No adverse effects to the mirtazapine
were observed or reported during this study.
The pharmacokinetic parameters for LD cats and age-matched
control cats are summarized in Table 1 and the serum mirtazapine
concentration-time graph is depicted in Figure 1. There was a statisti-
cally significant difference in Tmax between LD cats and age-matched
control cats (P = .03). AUC was not significantly different between
the two groups; however, the calculated half-life of LD cats was sig-
nificantly increased (P < .002) compared with age-matched control
cats (Figure 2). There was a correlation between serum ALT activity
(P = .002; r = .76), serum ALP activity (P < .0001; r = .89), and serum
total bilirubin concentration (P = .0008; r = .81) when compared with
the serum half-life of mirtazapine.
3.2 | In vitro studies
The average age of LD cats from which microsomes were collected
was 3 +/– 1.5 years (range 2–5 years). There was 1 spayed female
cat and 2 castrated male cats. The average age of cats without LD
from which microsomes were collected was 6.1 +/– 3.2 years (range
2.5–10 years). There were 2 spayed female cats and 2 castrated
male cats. Values for serum ALT activity, serum ALP activity, serum
total bilirubin concentration, and serum albumin concentration for
cats from which microsomes were collected are presented in
Table 2.
When liver microsomes from cats without and without LD were
incubated with mirtazapine, there was a significant difference in the
slope of the line representing the rate of loss (kel) of mirtazapine
between LD cats (–0.0022 min−1, CI: −0.0050 to 0.00054 min−1)
and cats without LD (0.01849 min−1, CI: −0.025 to −0.012 min−1;
P = .002; Figure 3). When in vitro half-life was calculated using the
slope of the regression line from both groups, microsomes from cats
with LD had an in vitro half-life of 313.6 versus 37.5 minutes for
microsomes from cats without LD representing a >8-fold reduction
in the metabolism of mirtazapine because of LD. The apparent
intrinsic clearance of mirtazapine for LD cats was 0.77 versus
6.5 mL/min/kg for cats without LD representing a >8-fold reduction
in the presence of LD.
FIGURE 1 Serum concentration-time profile for 1.88 mg mirtazapine
administered PO once to cats with LD (n = 11) and age-matched con-
trol cats (n = 11)
TABLE 1 Median and range clinicopathologic variables and
mirtazapine pharmacokinetic parameters of cats with LD and healthy
age matched control cats after cats received 1.88 mg
mirtazapine PO once
Liver
Group (n = 11)
Age-Matched
Control (n = 11)
Median (range) Median (range)
Dose mg/kg 0.45 (0.22–0.58) 0.48 (0.28–0.62)
ALT (IU/L) 407 (138–1690) 45 (30–72)
ALP (IU/L) 233 (24–454) 29 (8–50)
T Bili (mg/dL) 4.3 (0.1–21.1) 0 (0-0.1)
Albumin (g/dL) 3.3 (2.8-3.9) 3.7 (3.2–3.9)
Cmax (ng/mL) 40.1 (26–87.3) 49.1 (32.2–80.2)
Tmax (hours) 4 (1–4) 1 (1–4)
AUC (ng/mL•h) 382 (215–1075) 440 (277–944)
Half-lifea 13.8 (7.9–61.4) 7.4 (6.7–9.1)
an = 7 in each group for half-life calculation.
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phospha-
tase; AUC, area under the curve (drug exposure); Cmax, maximum
serum concentration; T bili, total bilirubin; Tmax, time to maximum
serum concentration.
FIGURE 2 When 1.88 mg mirtazapine was administered once PO to
cats with LD and age-matched control cats without LD, the calculated
half-life of LD cats (n = 7) was significantly increased compared with
age-matched control cats (n = 7; P < .002)
TABLE 2 Median and range clinicopathologic variables of cats with
and without LD from which liver microsomes were collected
LD Group (n = 3) Non-LD Group (n = 4)
Median (range) Median (range)
ALT (IU/L) 469 (137–693) 63 (19–76)
ALP (IU/L) 159 (112–230) 52 (50–68)
T Bili (mg/dL) 8.1 (0.1–10.5) 0.1 (0–0.1)
Albumin (g/dL) 2.5 (1.9–3.9) 3.3 (2.0–3.5)
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransfer-
ase; T bili, total bilirubin.
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4 | DISCUSSION
The purpose of the study was to assess the pharmacokinetics of mir-
tazapine in LD cats in comparison to healthy age-matched control cats
using both a limited sampling method in vivo and liver microsome
assays in vitro. In cats where a limited sampling method was used to
predict pharmacokinetics, the calculated half-life was significantly pro-
longed in LD cats compared with healthy age-matched control cats.
Additionally, LD cats had significantly longer time to maximum serum
concentration than did age-matched control cats. When mirtazapine
was incubated with liver microsomes from LD cats and cats without
LD, metabolism of mirtazapine in the microsomes of LD cats was pro-
longed in comparison to cats without LD.
Overall, the findings in our study are consistent with pharmacoki-
netic changes in humans as a result of LD. In humans, hepatic impair-
ment results in a 33% decrease in mirtazapine clearance and a 39%
prolongation in the half-life of mirtazapine (mean 44 +/– 4.8 hours in
LD versus 31.6 +/– 7.5 hours in healthy age-matched controls).2,7 In
our study in LD cats, a 185% prolongation in the half-life of mirtaza-
pine was seen (mean 21.7 +/– 18.8 hours versus 7.6 +/– 0.9 hours in
healthy age-matched controls). Time to maximum serum concentra-
tion is similar between humans with LD and healthy age-matched
controls, unlike in our study where LD cats had prolonged time to
maximum serum concentration. The reason for this is unknown,
although factors associated with LD such as altered gastrointestinal
motility and decreased intestinal perfusion secondary to portal hyper-
tension might be involved. A limitation to the present study is that
only 2 time points were evaluable for these parameters (1 or 4 hours)
and thus might not accurately represent the true values. The time
points were chosen based on an ability to accurately predict the over-
all exposure (AUC0-infinity) with minimal sampling and thus there was a
tradeoff in accurate prediction of true Cmax and Tmax. However, the
Tmax predicted for healthy control cats in this study does closely
match the Tmax measured in healthy controls from previous studies
(Table 3).
An interesting finding in this study is that the in vitro experiments
with liver microsomes recapitulated in vivo pharmacokinetic findings,
confirming that the increased half-life measured in LD cats can be
explained, at least in part, by a reduction in the intrinsic hepatic clearance
of mirtazapine in these cats. Microsomes have the potential as a valuable
tool to explore factors that affect drug metabolism as well as potential
drug interactions. Important future directions to better inform feline
pharmacology would be exploration and identification of the specific
cytochrome P450 activities that are dysfunctional in LD, and whether
FIGURE 3 Mirtazapine metabolism in liver microsomes from cats with and without LD. A, Measured mirtazapine concentrations at various time
points during in vitro metabolism. B, Nonlinear regression of ln-transformed percent remaining values to calculate the in vitro elimination rate (k).
There is a statistically significant difference between the slopes of the regression lines representing the in vitro elimination rate of mirtazapine
(ANOVA; P = .002)
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this varies depending on the type of LD. This is particularly important as
in humans, alterations in cytochrome P450 activities have been shown
to be non-uniform and variable depending on disease type and severity.8
Given the results of this and previous studies on mirtazapine in
cats, the age and disease status of cats should be taken into account
when prescribing mirtazapine. A comparison of pharmacokinetic data
for mirtazapine across age and disease in cats is presented in Table 3.
In a previous study, the mean half-life of mirtazapine was determined
to be nine hours in healthy cats, and once daily 1.88 mg dosing did
not result in significant drug accumulation.4 In another pharmacoki-
netic study evaluating mirtazapine in cats with chronic kidney disease,
it was determined that kidney disease can prolong the clearance and
half-life of mirtazapine.3 The mean half-life of mirtazapine was deter-
mined to be fifteen hours in cats with kidney disease, and based on
the results of this study, decreased dosing frequency (ie, every
48 hours) of mirtazapine in cats with kidney disease has been recom-
mended. In our study, because of the significant effects of kidney dis-
ease on mirtazapine pharmacokinetics, cats with concurrent kidney
disease were excluded to eliminate this variable from the analysis.
The study has several limitations that should be considered when inter-
preting results. The measured variables (ALT, ALP, total bilirubin) might not
be the best evaluation of liver function and fasting and postprandial bile
acid levels were not evaluated in the cats with LD in this study. However,
currently no gold standard of liver function exists to inform adjustment of
dose regimens in humans with liver dysfunction.8 Diagnostic imaging of the
liver, fine needle aspirate or biopsy was also not performed in all of the cats
in the LD so further conclusions cannot be drawn regarding what type of
LD was present or the relationship to mirtazapine metabolism.
In our study, blood work was not re-evaluated after administration
of mirtazapine as only 1 dose was administered. In humans, mirtazapine
rarely causes an idiosyncratic increase in ALT that resolves with discon-
tinuation of the drug.9 In a pharmacodynamic study of mirtazapine in
cats with chronic kidney disease, one cat developed an increased ALT
activity with no associated clinical signs that resolved with discontinua-
tion of the drug.10 It is unknown if there is increased risk of idiosyn-
cratic liver enzymes elevation if values are already increased at the time
of mirtazapine administration. A challenge of enrollment was that
owners were commonly reluctant to return their cat to the clinic for the
24 hours blood sample, thus the calculation of predicted half life, which
required a 24 hours time point, was based on a subset of 7 cats with
LD and the concomitant 7 age-matched control cats.
An additional limitation of the study was that it was not feasible
to collect liver microsomes from age-matched non-LD cats, and this
may have introduced some potential bias. In an attempt to minimize
this bias, liver microsomes were collected from non-LD cats who
were a range of ages. It is also noted that the method used for eval-
uation of in vitro metabolism does not account for any drug clear-
ance via direct phase II metabolic reactions and thus the possibility
of alterations in direct conjugation of mirtazapine cannot be
assessed in our study.
In conclusion, when 1.88 mg of mirtazapine was administered once
PO to LD cats and age-matched control cats, cats with LD displayed
prolonged time to maximum serum concentration and prolonged calcu-
lated half-life. This observation was further supported in vitro by the
demonstration of delayed metabolism of mirtazapine by liver micro-
somes from LD cats. These findings should be taken into consideration
when prescribing mirtazapine to feline patients with LD.
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TABLE 3 Comparative pharmacokinetic parameters of single dose oral 1.88 mg mirtazapine in cats of difference ages and disease states3,4
Healthy Young Cats4
Healthy Geriatric Cats
(Age-match to CKD)3 CKD Cats3
Healthy Cats
(Age-match to Liver) Cats with LD
Mirtazapine PO
Administration
(capsule formulation;
0.44 mg/kg)
Mirtazapine PO
Administration
(capsule formulation;
0.44 mg/kg)
Mirtazapine PO
Administration
(capsule formulation;
0.51 mg/kg)
Mirtazapine PO
Administration
(capsule formulation;
0.47 mg/kg)
Mirtazapine PO
Administration
(capsule formulation;
0.43 mg/kg)
PK Parameter N = 4 N = 6 N = 6 N = 11 N = 11
Tmax (h) 1.0 (1.0–4) 1.0 (1.0–4) 1.0 (0.5-1.5) 1.0 (1.0–4) 4.0 (1.0–4)
Cmax (ng/mL) 73.1 (45.5) 79.6 (21.7) 110.6 (30.8) 54.0 +/– 15.8 43.9 +/– 18.8
AUC0-∞ (ng*h/mL) 407.4 (102.1) 1320.4 (236.0) 1701.2 (301.3) 470 +/– 182 434 +/– 230
Half life (h) 10.3 (2.3) 12.1 (1.1) 15.2 (4.2) 7.6 +/– 0.9 21.7 +/– 18.8
Abbreviations: AUC, area under the curve (drug exposure); Cmax, maximum serum concentration; CKD, chronic kidney disease; PO, oral; Tmax, time
to maximum serum concentration.
Serum PK parameter values are reported as mean (SD), except for Tmax, which is reported as median (min–max).
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